<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00841828</url>
  </required_header>
  <id_info>
    <org_study_id>GEICAM/2006-14</org_study_id>
    <secondary_id>2007-007031-13</secondary_id>
    <nct_id>NCT00841828</nct_id>
  </id_info>
  <brief_title>Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients</brief_title>
  <official_title>A Multicentre, Randomised Phase II to Compare Epirubicin (E) &amp; Cyclophosphamide (C) Treatment Plus Docetaxel (D) &amp; Trastuzumab vs. E &amp; C Treatment Plus D &amp; Lapatinib in Women With Primary Resectable or Locally Advanced HER2+ Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II randomized multicenter trial to compare Epirubicin and Cyclophosphamide plus
      Docetaxel and Trastuzumab with Epirubicin and Cyclophosphamide plus Docetaxel and Lapatinib
      for patients with positive HER2 and resectable or locally advanced breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open label, randomized phase II trial. Women with primary cancer and
      overexpression of Human Epidermal Growth Factor Receptor 2 (HER2) who have not received prior
      treatment for invasive breast cancer will be included. The study will analyze the efficacy
      and tolerance of Lapatinib and Docetaxel and the Trastuzumab and Docetaxel after 4 cycles of
      Epirubicin and Cyclophosphamide in patients with breast cancer HER2 positive.

      102 patients will be stratified according to tumor size and estrogen receptor status
      (positive or negative) to be randomized to receive one of the following treatment arms:

        -  Experimental arm: Epirubicin 90mg/m2 in combination with cyclophosphamide 600mg/m2
           intravenous (IV) every 21 days for 4 cycles, followed by oral Lapatinib 1250mg once a
           day plus docetaxel 100mg/m2 IV every 21 days for 4 cycles with the administration of
           granulocyte-colony stimulating factor (G-CSF) between days 2 and 7 or on day +1
           according to the G-CSF used by the site.

        -  Control arm: Epirubicin 90mg/m2 in combination with cyclophosphamide 600mg/m2 IV every
           21 days for 4 cycles, followed by a loading dose of Trastuzumab 8mg/kg IV followed by
           Trastuzumab 6mg/kg IV every 3 weeks plus docetaxel 100mg/m2 IV every 21 days for 4
           cycles with the administration of G-CSF between days 2 and 7 or on day +1 according to
           the G-CSF used by the site.

      Treatment duration: The patients will be in treatment for an average of 6 months for both
      arms.

      Study population: Patients with operable or locally advanced breast cancer, HER2 positive who
      are candidates to receive neoadjuvant treatment and who have not received pre-treatment for
      invasive breast cancer.

      Population in study and number total of patients:

      The aim is to determine if neoadjuvant treatment with selective therapy can increase the
      complete pathological response (pCR) in breast cancer by the determination of molecular
      markers in the tumoral sample before treatment. Then, and between 3 and 4 weeks after the
      last administration of Docetaxel, and 24 hours after the administration of Lapatinib, surgery
      will be performed and in the surgical sample will be determined the molecular markers
      analyzed before of the treatment in the tumor sample.

      Patients with HER2 positive, defined as immunohistochemistry 3+ or positive fluorescence in
      situ hybridization (FISH), will be included. If immunohistochemistry 2+ it will be necessary
      to confirm the HER2 positive status by FISH. All results will be reevaluated later in the
      central laboratory.

      Statistical consideration: The sample size has been calculated using the 2-stage Simon method
      and with pathological complete response (pCR) as the primary study end point. Sample size has
      been based on the null hypothesis of a pCR of 40% and an alternative hypothesis of a pCR of
      60%. Assuming an alpha error of 0.05 and a test power of 80%, 92 evaluable patients will be
      required to be recruited and retained in the study. Sixteen patients per arm will be included
      in the first stage, for at least eight pCR per arm to be seen, and 30 additional patients per
      arm will be included in the second stage for a total of 46 evaluable patients in each arm.
      Assuming a 10% drop-out rate, 102 patients will be recruited.

      The objective of the random distribution to treatment arms is to select the most active arm
      for a subsequent development. It is based on a standard of pCR of 40%, in order to detect an
      increase in the pCR rate of 60% in both arms, it would be necessary to include 46 patients in
      each arm (Simon's method in 2 stages (Optimal design)). It has been considered an error a =
      0.05 and a power 80% statistics. Therefore, in the first stage it would be necessary to
      include 16 patients in each arm if we found more than 7 patients with pCR in each arm we will
      continue including until reaching the 46 in each arm. The results will be significant if we
      find at least 23 patients with pCR in each arm. Assuming that 10% of patients are not
      evaluable, the number The total number of patients to be included is 102 patients (51
      patients per arm of treatment).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Pathological Response (pCR) Rate in Breast and Axilla According to the Miller&amp;Payne Criteria (G5-A and G5-D).</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Within 3-4 weeks after last docetaxel dose the surgery was performed to evaluate pathological response. According to the Miller&amp;Payne Criteria, pCR in node-negative patients is a grade 5-A and in node-positive patients is a grade 5-D.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Clinical Response Rate (ORR)</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Overall clinical response was evaluated according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria (Therasse et al, 2000). Is defined as the sum of Complete responses plus Partial responses.
It was evaluated after the fourth EC cycle and before surgery using ultrasound, mammography, or MRI.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epirubicin + Cyclophosphamide -&gt; Docetaxel + Lapatinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epirubicin + Cyclophosphamide -&gt; Docetaxel + Trastuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Ellence</other_name>
    <other_name>Pharmorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Tykerb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <arm_group_label>Control</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signature of the written informed consent.

          2. Histological documentation of breast cancer.

          3. Stage I (T1, N0M0), IIA (T2N0M0); IIB (T2N1M0, T3N0M0), IIIA (TXN2M0) and IIIB
             (T3N1M0, T4NXM0) primary resectable breast cancer or locally advanced breast cancer.

          4. HER2-positive breast cancer, defined as immunohistochemistry (IHQ) 3+ or positive
             FISH. When IHQ 2+ HER2 status must be assessed by FISH.

          5. The patient granted her consent for taking a biopsy before treatment

          6. The patient granted her consent for sending two tumor samples to central laboratory
             for molecular sub study.

          7. Two weeks prior randomization pregnancy test negative for women of childbearing
             potential.

          8. Women of childbearing potential must use adequate contraceptive measures during
             participation into study. Oral, injectable or implant hormonal contraceptives measure
             are not permitted.

          9. A World Health Organization (WHO) performance status of 0 or 1 (Karnofsky ≥ 80)

         10. Age &gt; 18 years.

         11. Absence of metastases disease

         12. Baseline Electrocardiography (EKG) 12 weeks prior to randomization. Baseline left
             ventricular ejection fraction (LVEF) value within limit of normal value for the
             institution or &gt; 50% of basal value

         13. Normal laboratory test 2 weeks prior to randomization:

             Haematology values: Neutrophil count ≥ 1,5 x109/l; Platelets ≥ 100 x 109/l;
             Haemoglobin ≥ 10mg/dl Biochemistry values: serum total bilirubin ≤ 1 x Upper Limit of
             Normal (ULN); Aspartate aminotransferase (AST) (SGOT) and Alanine aminotransferase
             (ALT) (SGPT) ≤ 2,5 x ULN; alkaline phosphatase ≤ 5 x ULN. Patients which AST and/or
             ALT value are &gt; 1,5 x ULN along with alkaline phosphatase value &gt; 2,5 x ULN will be
             not included into the study.

             Renal function: serum creatinine ≤ 175 µmol/l (2 mg/dl). If the value is borderline,
             clearance creatinine must be ≥ 60 ml/min

         14. 12 weeks prior to randomization the following assessments and procedures must be
             fulfilled: Bilateral mammography; Magnetic resonance imaging (MRI) Breast and
             axillary; Chest X-Ray (posterioanterior and lateral); Abdominal ultrasound; Chest
             CT-Scan; Abdominal CT-Scan. Bone Scan (if applicable)

         15. Patients must be accessible for treatment and follow up

        Exclusion Criteria:

          1. Patients with lumpectomy, partial mastectomy, modified radical mastectomy are not
             allowed to include into study.

          2. Prior Immunotherapy, hormonal therapy and chemotherapy for breast cancer is not
             allowed.

          3. Prior therapy with anthracycline and taxanes (paclitaxel and docetaxel) is not
             permitted for any neoplasia.

          4. Prior radiotherapy for breast cancer.

          5. Bilateral invasive breast carcinoma

          6. Pregnant or nursing patients. Negative pregnant test (serum or urine) 14 days prior to
             randomization.

          7. HER 2 negative breast cancer

          8. Patients of childbearing potential must be use adequate contraceptive measures during
             study treatment. No hormonal contraceptive measure is permitted.

          9. Any M1 breast cancer

         10. Any motor or sensorial neurotoxicity grade ≥ 2 according to National Cancer Institute
             Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.

         11. Serious cardiac illness or medical conditions: Congestive heart failure, angina
             pectoris requiring specific treatment, myocardial infarction 1 year prior to enroll in
             the study; poorly controlled hypertension or high-risk uncontrolled arrhythmias.

             History of significative neurological or psychiatric disease (psychotic, dementia or
             attack) what is unable to patient to grant her informed consent.

             Uncontrolled severe Infection Uncontrolled diabetes mellitus, active peptic ulcer

         12. Current malignancy or previous malignancy other that breast cancer. Exception cell
             carcinoma of the skin no melanoma, carcinoma in situ of the cervix or any other cancer
             in the past 10 years.

         13. Long term treatment with corticoids except 6 months prior to inclusion in the study
             and low doses (≤ 20 mg methylprednisolone or equivalent)

         14. Corticoid use contraindication

         15. Concomitant hormonal replacement therapy. Previous treatment should be interrupted
             before inclusion into study.

         16. Cardiopathy what stops patient taking Docetaxel and Trastuzumab: myocardial infarction
             recorded; angina pectoris requiring specific treatment; any congestive heart failure
             recorded; arrhythmia grade 3 or 4 according to NCI CTCAE version 3; any relevant
             valvular disease; chest X ray which shows cardiomegaly or EKG which shows ventricular
             hypertrophy unless LVEF value has been ≥ lower normal limit in the last 3 months.

         17. Poorly controlled hypertension (systolic &gt; 180 mm Hg or diastolic &gt; 100 mm Hg). The
             patients with controlled hypertension under treatment can be included into study

         18. Patients under treatment of arrhythmia, angina or congestive heart failure with drug
             which modifies cardiac conduction (after digital, beta blocker or inhibitors calcium
             channel) are excluded. However if these drugs are took for arterial tension the
             patient can be included into study.

         19. The patient must interrupt concomitant treatment with hormonal therapy ej. raloxifene,
             tamoxifen and selective estrogen receptor modulators (SERM) prior to randomization.

         20. Concomitant use of inhibitors and inductors of enzyme CYP3A4 complex (ketoconazole,
             itraconazole or grape juice; rifampicin, carbamazepin or fenitoin) are not permitted.
             Also, drug are substrate of enzyme CYP2C8 complex is not permitted along with
             lapatinib treatment.

         21. Concurrent treatment with an investigational agent or participation in another
             therapeutic clinical trial within 30 days prior to randomization into study.

         22. Concomitant treatment with other anticancer therapy

         23. Hypersensitivity reaction to drugs trastuzumab, lapatinib or their excipients.

         24. Male
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clínico Universitario de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clínico Universitario Virgen de la Victoria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Granollers</name>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <zip>08400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xarxa Asistencial de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporación Sanitaria Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Espíritu Santo</name>
      <address>
        <city>Santa Coloma De Gramenet</city>
        <state>Barcelona</state>
        <zip>08923</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologikoa</name>
      <address>
        <city>Donostia-San Sebastián</city>
        <state>Guipuzcoa</state>
        <zip>20012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral Cíes</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz De Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de Galicia</name>
      <address>
        <city>A Coruña</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Yagüe</name>
      <address>
        <city>Burgos</city>
        <zip>09005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.geicam.org</url>
    <description>Sponsor's website</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>February 9, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2009</study_first_posted>
  <results_first_submitted>April 28, 2014</results_first_submitted>
  <results_first_submitted_qc>March 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2018</results_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2-positive breast cancer</keyword>
  <keyword>Lapatinib</keyword>
  <keyword>Neoadjuvant</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: EC -&gt; D + Lapatinib</title>
          <description>EC -&gt; D + Lapatinib
Drugs plus Biological
Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -&gt; Docetaxel + Lapatinib each 21 days for 4 cycles</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: EC -&gt; D + Trastuzumab</title>
          <description>EC -&gt; D + Trastuzumab
Drug plus Biological
EC each 21 days for 4 cycles -&gt; Docetaxel + Trastuzumab each 21 days for 4 cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: EC -&gt; D + Lapatinib</title>
          <description>Epirubicin and Cyclophosphamide (EC) followed by Docetaxel (D) and Lapatinib
Drugs plus Biological
Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles followed by Docetaxel and Lapatinib each 21 days for 4 cycles</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: EC -&gt; D + Trastuzumab</title>
          <description>Epirubicin and Cyclophosphamide (EC) followed by Docetaxel (D) and Trastuzumab
Drug plus Biological
Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles followed by Docetaxel and Trastuzumab each 21 days for 4 cycles</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="30" upper_limit="79"/>
                    <measurement group_id="B2" value="48.5" lower_limit="32" upper_limit="74"/>
                    <measurement group_id="B3" value="48" lower_limit="30" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Premenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estrogen Receptor</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor Size</title>
          <units>centimeters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" lower_limit="1" upper_limit="15.8"/>
                    <measurement group_id="B2" value="3.3" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="B3" value="3.3" lower_limit="1" upper_limit="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nodal Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>N0=no regional lymph node metastases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1=metastases 1-3 axillary lymph node/s</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2=metastases in 4-9 axillary lymph nodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Pathological Response (pCR) Rate in Breast and Axilla According to the Miller&amp;Payne Criteria (G5-A and G5-D).</title>
        <description>Within 3-4 weeks after last docetaxel dose the surgery was performed to evaluate pathological response. According to the Miller&amp;Payne Criteria, pCR in node-negative patients is a grade 5-A and in node-positive patients is a grade 5-D.</description>
        <time_frame>Up to 16 weeks</time_frame>
        <population>Arm 1: 1 patient not included in this analysis due to negative Fluorescence in situ hybridization (FISH) result.
Arm 2: 2 patients not included in this analysis due to negative Fluorescence in situ hybridization (FISH) result.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: EC -&gt; D + Lapatinib</title>
            <description>EC -&gt; D + Lapatinib
Drugs plus Biological
Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -&gt; Docetaxel (D) + lapatinib each 21 days for 4 cycles)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: EC -&gt; D + Trastuzumab</title>
            <description>EC -&gt; D + Trastuzumab
Drug plus Biological
Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -&gt; Docetaxel (D) + Trastuzumab each 21 days for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Pathological Response (pCR) Rate in Breast and Axilla According to the Miller&amp;Payne Criteria (G5-A and G5-D).</title>
          <description>Within 3-4 weeks after last docetaxel dose the surgery was performed to evaluate pathological response. According to the Miller&amp;Payne Criteria, pCR in node-negative patients is a grade 5-A and in node-positive patients is a grade 5-D.</description>
          <population>Arm 1: 1 patient not included in this analysis due to negative Fluorescence in situ hybridization (FISH) result.
Arm 2: 2 patients not included in this analysis due to negative Fluorescence in situ hybridization (FISH) result.</population>
          <units>percentage of participants with pCR</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" lower_limit="11.9" upper_limit="35.1"/>
                    <measurement group_id="O2" value="47.9" lower_limit="33.8" upper_limit="62.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Clinical Response Rate (ORR)</title>
        <description>Overall clinical response was evaluated according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria (Therasse et al, 2000). Is defined as the sum of Complete responses plus Partial responses.
It was evaluated after the fourth EC cycle and before surgery using ultrasound, mammography, or MRI.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Arm 1: 1 patient not included in this analysis due to negative Fluorescence in situ hybridization (FISH) result.
Arm 2: 2 patients not included in this analysis due to negative Fluorescence in situ hybridization (FISH) result.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: EC -&gt; D + Lapatinib</title>
            <description>EC -&gt; D + Lapatinib
Drugs plus Biological
Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -&gt; Docetaxel (D) + lapatinib each 21 days for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: EC -&gt; D + Trastuzumab</title>
            <description>EC -&gt; D + Trastuzumab
Drug plus Biological
Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -&gt; Docetaxel + Trastuzumab each 21 days for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Clinical Response Rate (ORR)</title>
          <description>Overall clinical response was evaluated according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria (Therasse et al, 2000). Is defined as the sum of Complete responses plus Partial responses.
It was evaluated after the fourth EC cycle and before surgery using ultrasound, mammography, or MRI.</description>
          <population>Arm 1: 1 patient not included in this analysis due to negative Fluorescence in situ hybridization (FISH) result.
Arm 2: 2 patients not included in this analysis due to negative Fluorescence in situ hybridization (FISH) result.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" lower_limit="49.4" upper_limit="76"/>
                    <measurement group_id="O2" value="77.1" lower_limit="65.2" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study treatment up to 24 week</time_frame>
      <desc>These Adverse Events are by patient (not per cycle). Only grades 3 and 4 are specified.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: EC -&gt; D + Lapatinib</title>
          <description>EC -&gt; D + Lapatinib
Drugs plus Biological
Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -&gt; Docetaxel (D) + lapatinib each 21 days for 4 cycles)</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: EC -&gt; D + Trastuzumab</title>
          <description>EC -&gt; D + Trastuzumab
Drug plus Biological
Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -&gt; Docetaxel (D) + Trastuzumab each 21 days for 4 cycles</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI-CTC v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils/granulocytes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>NCI-CTC v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nausea and Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Emilio Alba</name_or_title>
      <organization>Department of Medical Oncology, Hospital Universitario Virgen de la Victoria</organization>
      <email>emilioalbac@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

